Dimensional Fund Advisors
IMDX

Dimensional Fund Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Dimensional Fund Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,012
Closed -$149K – 3511
2022
Q1 		$149K Sell
5,012
-323
-6% -$10.3K ﹤0.01% 3347
2021
Q4 		$232K Sell
5,335
-7,235
-58% -$416K ﹤0.01% 3321
2021
Q3 		$895K Buy
12,570
+6,347
+102% +$583K ﹤0.01% 3067
2021
Q2 		$714K Buy
+6,223
New +$608K ﹤0.01% 3091

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Dimensional Fund Advisors's IMDX Position: Q2 2022 in Review

Dimensional Fund Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 5,012 shares — an estimated $149K sold.

Dimensional Fund Advisors first reported a position in IMDX in Q2 2021 and held it in 4 quarters. The position peaked at $895K in Q3 2021. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

  • Dimensional Fund Advisors reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Dimensional Fund Advisors sold 5,012 Insight Molecular Diagnostics shares in Q2 2022, an estimated $149K.
  • Dimensional Fund Advisors first reported a position in Insight Molecular Diagnostics in Q2 2021 and held it in 4 quarters.
  • Dimensional Fund Advisors's Insight Molecular Diagnostics position peaked at $895K in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on Dimensional Fund Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.